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Tourette syndrome (TS) is a common neuropsychiatric disorder in children character-
ized by multiple motor and vocal tics that fluctuate in severity and lasting for at least 
1 year. Boys are more commonly affected than girls. Symptoms usually begin with 
simple motor or vocal tics which then evolve into more complex motor and vocal 
tics over time. Premonitory sensory urges are common in children over the age of 
8 years, and these urges help distinguish tics from symptoms of other movement 
disorders. Common comorbidities of TS include attention deficit hyperactivity dis-
order, obsessive-compulsive disorder and learning difficulties. Several genes have been 
assessed as candidate genes for TS; environmental factors such as stress and strepto-
coccal infections might also contribute to its etiology. The pathophysiology of TS 
mainly involves dysfunction of basal ganglia-related circuits and hyperactive dopami-
nergic innervations. A thorough history assessment and neurological examination are 
important for the correct diagnosis and differentiation from other movement disor-
ders. Treatment for TS should focus on improving the patient’s social functioning, mini-
mizing the impairment from cormobid disorders, and controlling tics, if they are 
severe. Commonly used medications for TS include α2-adrenergic agonists and atyp-
ical neuroleptics. Habit reversal therapy is an effective option for TS, and repetitive 
transcranial magnetic stimulation may be a promising approach for severe cases.
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1.  Introduction
Tourette syndrome (TS) is a developmental neuropsy-
chiatric disorder characterized by multiple brief, 
stereotypical but nonrhythmic movements and by 
vocalizations called tics, with a duration of at least 
1 year.1 The onset of tic symptoms in TS typically 
occurs during early childhood, and the disorder af-
fects 1−3% of Western2 and 0.56% of Taiwanese3 
school-aged children. Boys are more commonly af-
fected than girls with a ratio of 9:2 in TS children 
in Taiwan.3 Transient tic disorder, manifested by 
tics that are present for less than 1 year, affects ap-
proximately 6−20% of children in lifetime prevalence. 
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Chronic tic disorders, which are characterized by 
either motor or vocal tics, but not both, occur in 
5% of school-aged children.4−6 The main features 
of TS are motor and vocal tics that wax and wane 
in severity. Motor and vocal tics occur in bouts pe-
riodically over the course of a day, and change in 
severity over weeks and months. Common comorbid-
ities include attention-deficit hyperactivity disor-
der (ADHD), obsessive−compulsive disorder (OCD), 
learning disabilities, disruptive behavior disorders, 
self-injurious behavior and sleep disturbances.2,3,7 
The severity of tics in TS children usually declines 
over the course of adolescence, but the comorbid-
ities may persist and often cause more functional 
impairment.8 In this article, we review the updated 
information about TS in children.
2.  Tic Symptoms and Natural History
Common motor tics include eye blinking, facial 
grimacing, nose twitching, jaw, neck, and shoulder 
or limb movements, while common vocal tics consist 
of sniffing, grunting and chirping, as well as throat 
clearing.9 Motor tics usually appear between the 
ages of 4 and 6 years, several years before the onset 
of vocal tics, which usually begin between 8 and 
12 years.10 With increasing age, motor tics may evolve 
into more elaborate movements (e.g., purposeful-
like movements or lewd gestures), and vocal tics 
often develop into repeating words (echolalia), or 
phrases (palilalia), or obscene words (coprolalia).11 
Motor and vocal tics often occur in discrete bouts 
over the course of a day, and change in severity 
over weeks and months.12 These bouts are charac-
terized by brief periods of stable inter-tic intervals 
of short duration, typically 0.5−1.0 seconds, and 
inter-bout intervals that last from minutes to 
hours.10,12 Speculation has focused on the “frac-
tal” occurrence of tics in time, such that the wax-
ing and waning course of tics over weeks to months 
might be the result of the same basic neurobiologi-
cal processes that underlie the occurrence of tics 
in bouts in the shorter time scale of seconds and 
minutes.11 In most patients, the course of worst tic 
severity falls between 7 and 15 years of age, after 
which the severity usually declines until early 
adulthood.10,13 By late adolescence or young adult-
hood, over one third of TS patients are virtually 
tic-free, less than half have minimal to mild tics, 
and less than a quarter have persistently moderate 
to severe tics.13 Slightly less than 5% of individuals 
may report experiencing worse tics during young 
adulthood than they did in childhood.
Many TS patients experience premonitory urges; 
a premonitory urge is a sensory phenomenon that 
occurs immediately prior to a tic, similar to the need 
to scratch or sneeze.14 Premonitory sensory urges 
often prompt the tics, and a momentary sense of 
relief frequently follows the successful perfor-
mance of a tic.15 Children under the age of 8−10 years 
are usually totally unaware of these sensory urges, 
and awareness increases with age. By 3 years after 
the onset of tics, these urges are present in as many 
as 90% of adolescents with TS.16 The shoulder girdle, 
throat, hands, midline of the stomach, front of the 
thighs and feet are “hot spots” for experiencing these 
premonitory sensory urges,14 which can sometimes 
prove more troublesome than the tics themselves, 
particularly in patients who are able to suppress the 
tics, but unable to resist the distracting urges.11 Ir-
respective of the use of medications or other treat-
ment, these urges typically subside as the tics 
improve.17
TS patients can suppress tics volitionally, or merge 
them into purposeful behaviors or utterances, 
though often at the expense of a build-up of inner 
tension leading to mental exhaustion.18 The ability 
to suppress tics usually increases as TS children grow 
up. The frequency and intensity of tics typically 
worsen during periods of stress, anxiety, excite-
ment and fatigue.19 Several studies of TS children 
have indicated that daily life stressors may play more 
important roles in future tic outcome than major 
life events.20 Elevated core body temperature is also 
associated with increased tic frequency in some 
patients.21 In contrast, tics are often alleviated dur-
ing periods that require attention and fine-motor 
movements, such as playing a musical instrument, 
dancing, or playing sports.19
Tics can also occur during sleep, which distinguish 
them from many other movement disorders; how-
ever tics are much diminished compared with those 
during awake periods. Polysomnographic studies 
have demonstrated that TS children displayed lower 
sleep efficiency and elevated arousal levels, and 
that those TS children with comorbid ADHD were 
additionally characterized by an increase in rapid 
eye movement sleep.22,23 Associated comorbidities, 
especially ADHD, are likely to contribute to these 
sleeping disturbances.24
3.  Comorbidity
Most TS children have other comorbidities, which 
often cause more impairment than the tic symptoms 
themselves. An epidemiological study in Taiwan re-
vealed that common comorbidities in elementary-
school-aged children with TS (aged 6−12 years) were 
ADHD (36%), mild self-injurious behaviors (27%), 
OCD (18%) and learning difficulties (9%).3 The prev-
alence of comorbid ADHD in all TS children may 
reach as high as 60−70%.25 The onset of hyperactive 
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symptoms of ADHD may precede the appearance of 
tics by around 2 years. The simultaneous occurrence 
of TS and ADHD symptoms has been associated with 
disruptive behaviors, academic difficulties, peer re-
jection and family conflict.26,27 Comorbid ADHD 
symptoms in childhood even correlate with a reduced 
quality of life and global functioning in early adult-
hood in patients with TS.28 However, studies investi-
gating the clinical course of ADHD in individuals with 
comorbid tic symptoms are still lacking.
Approximately 30−50% of TS children will expe-
rience comorbid OCD.13 Obsessive compulsive (OC) 
symptoms associated with tics generally have a pre-
pubertal age at onset and can predate the onset of 
tics.11 However, the period of worst OC symptoms 
usually occurs on average 2 years after the period 
of worst tics.13 When present, these symptoms are 
usually practiced in secret and are most disabling 
in the home environment.29 OC symptoms can lead to 
periods of depression and impairment in adaptive, 
as well as emotional functioning.30 Analysis of ver-
tical transmission patterns in families has revealed 
that OCD and TS may share some underlying genetic 
vulnerabilities.31 Adulthood outcome studies have 
also indicated that childhood-onset OCD patients 
with comorbid tics may achieve remission of OC 
symptoms by adulthood.32 These data suggest that 
OC symptoms in children with OCD and comorbid tics 
may follow a similar developmental trajectory to 
the tics themselves.33
Learning difficulties are not uncommon in TS 
children. Indeed, a database of 5450 subjects with 
TS showed that the prevalence of comorbid learn-
ing difficulties was about 22.7%.34 Individuals with 
TS can show profound difficulties in fine motor con-
trol, motor inhibition and visual motor integration.35 
TS children have also been reported to display def-
icits in procedural memory and habit learning rela-
tive to normal controls.36,37 Comorbid ADHD symptoms 
in TS children are also the main cause of learning 
difficulties.
Children with TS experience comorbid depres-
sion and anxiety disorders in adolescence and early 
adulthood more frequently than the general popu-
lation does.28 Roughly 40% of TS children will expe-
rience depression or a non-OCD anxiety disorder.13 
Children with TS and their parents should therefore 
be educated to recognize the signs and symptoms 
of these conditions.33
4.  Etiology
4.1.  Genetic factors
Genetic studies in twins and families provide com-
pelling evidence that genetic factors, particularly 
polygenic hereditary patterns, are involved in the 
vertical transmission of TS.31 Linkage analyses have 
suggested the importance of several chromosomal re-
gions, including 11q23, 4q34−35, 5q35 and 17q25.38,39 
Several identity-by-descent studies of TS popula-
tions have implicated regions near the centromere 
of chromosome 2, and on 6p, 8q, 11q, 14q, 20q and 
21q, as well as on the X chromosome.40−42 Some can-
didate genes have been assessed, including those 
for various dopamine receptors (DRD1, DRD2, DRD4, 
and DRD5), dopamine transporter, various noradren-
ergic genes (ADRA2a, ADRA2C, DBH, and MAO-A), 
and a few serotonergic genes (5HTT).43,44 A study 
in Taiwan demonstrated that the dopamine receptor 
D2 gene with Taq I DRD2 and DRD2 (H313H) poly-
morphisms was associated with TS in children.45 
More recently, the Slit and Trk-like family member 
1 gene (SLITRK1) and the L-histidine decarboxylase 
gene (HDC) have also been identified as possible vul-
nerability genes for TS.46,47 However, one genetic 
analysis of 160 Taiwanese children with TS failed to 
detect any mutation in the whole SLITRK1 gene se-
quence, including the promoter, the 3-untranslated 
region and the 5-untranslated region.48
4.2.  Epigenetic factors
Many epigenetic factors have been implicated in 
the pathogenesis of TS, including perinatal insults, 
exposure to androgens and psychologic stress, as 
well as post-infectious autoimmune mechanisms.9 
Perinatal hypoxic/ischemic events and prenatal ma-
ternal smoking have been reported as risk factors 
for developing TS.49,50 Male sex is also recognized 
as a risk factor for TS, based on clinical observations 
of male dominance in the prevalence of TS. However, 
frequent male-to-male transmission within fami-
lies seems to rule out the possibility of an X-linked 
inheritance pattern. This observation has led to 
the hypothesis that androgen exposure during criti-
cal periods in fetal brain development is a risk factor 
for the development of TS.51
Patients with TS usually suffer increased psy-
chosocial stress, and some prospective longitudinal 
studies also indicated that antecedent stress could 
increase future tic and OC symptom severity.52 The 
hypothalamic-pituitary-adrenal axis in TS patients 
seems to be more responsive to stress than in nor-
mal subjects, resulting in a significant elevation of 
cerebrospinal fluid corticotropin-releasing factor and 
a greater circadian change in saliva cortisol levels.53,54 
However, further investigations are needed to elu-
cidate the neurobiological mechanisms by which 
stress contributes to the pathobiology of TS.
A postinfectious etiology for TS has been stud-
ied for years, and group A β-hemolytic streptococ-
cal (GABHS) infection is the most likely candidate 
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involving the onset of TS.55 GABHS are known to 
trigger several immune-mediated diseases, such as 
Sydenham’s chorea and pediatric autoimmune neu-
ropsychiatric disorder associated with streptococcal 
infection (PANDAS), both of which share symptoms 
similar to those seen in TS and OCD. One possible 
mechanism is that antibodies directed against GABHS 
could attack brain cells due to molecular mimicry.56 
A case-control study of 144 children with diagnoses 
of TS, OCD, or tic disorders revealed that these pa-
tients were more likely than controls to have had a 
streptococcal infection in the 3 months prior to 
the onset date. Having multiple GABHS infections 
within a 12-month period was associated with a 
13-fold increased risk for developing TS.55 Increased 
proinflammatory cytokines (tumor necrosis factor-α, 
interleukin-12), elevated synthesis of antineuronal 
antibodies, and decreased number of regulatory 
T-cells have also been reported to correlate with 
disease severity in TS patients.57
Interestingly, a study of 72 Taiwanese children 
with TS demonstrated a higher risk of having allergic 
diseases (e.g., allergic rhinitis, asthma, atopic der-
matitis) than controls.58 However, the association 
between the waxing-and-waning course of TS and 
the seasonal variation in allergic diseases requires 
further investigation.
5.  Hypotheses for Pathophysiology of TS
The pathological processes of tics remain unclear, but 
several hypotheses have been proposed. Dysfunction 
of the basal ganglia has long been suggested to be 
the major cause of tic symptoms. The basal ganglia 
form a network of interconnected subcortical struc-
tures, including the striatum, globus pallidus, sub-
stantia nigra and subthalamic nucleus. The striatum 
receives input from the cerebral cortex, thalamus, 
hippocampus, midbrain and other structures. It 
then relays processed information to the globus pal-
lidus and substantia nigra, which in turn project to 
the thalamus and then back to the cortex (Figure 129). 
The cortico-striato-thalamo-cortical circuits play a 
critical role in coordinating motor and cognitive 
processes, as well as in habit formation.59 Malfunction 
of these circuits may contribute to the fragmentary 
semi-autonomous behaviors that manifest as tics.60
Several volumetric magnetic resonance imaging 
studies have reported that TS children had smaller 
caudate volumes than age-matched controls.61,62 
Caudate volumes of TS patients during childhood, as 
demonstrated by magnetic resonance imaging, were 
not correlated with tic severity in childhood, but 
were strongly predictive of the severity of tic and 
OC symptoms in early adulthood, with an inverse 
association.63 The correlation between reduced 
caudate volume and tic severity in adulthood, but 
not in childhood, supports the concept of a role 
for developmental basal ganglia abnormalities in 
TS. Functional neuroimaging studies in TS patients 
have implicated the basal ganglia, thalamus and 
prefrontal cortical regions as being associated 
with abnormal cerebral activity during conscious 
suppression of tics.64,65 These studies also revealed 
that activation of the caudate nucleus was inversely 
correlated with tic severity, suggesting that a re-
duced ability of the basal ganglia to suppress corti-
cal activity may be linked to increased tic severity.
The majority of cells in the striatum (around 80% 
in humans) are medium spiny neurons (MSNs), which 
receive excitatory glutamatergic signals from the cor-
tex and project GABAergic inhibitory signals out of 
the striatum to the globus pallidus and the substantia 
nigra (Figure 266).67 Several other less abundant stri-
atal neurons play critical roles in modulating the 
firing of most MSNs, including cholinergic tonically 
active neurons (TANs) and GABAergic parvalbumin-
positive fast-spiking interneurons (FSNs).68,69 A recent 
postmortem analysis of the brains of five individuals 
severely affected with TS demonstrated a 50−60% 
reduction in both FSNs and TANs in the caudate and 
putamen.70 A decreased inhibitory influence of TANs 
and FSNs over MSNs could allow cortical sensori-
motor inputs to activate MSNs more easily, eliciting 
premonitory sensory urges and tics in sequence. 
These alterations may indicate a developmental de-
fect in the migration of GABAergic neurons from 
their birthplace in the primordial striatum (the lat-
eral and medial ganglionic eminences), but further 
studies are needed to confirm this hypothesis.9
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Figure 1 Schematic diagram of the major connections 
of the basal ganglia (adapted from Leckman, 200229). 
GPe = globus pallidus, pars externa; GPi = globus pallidus, 
pars interna; SNr = substantia nigra, pars reticulata.
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Dopaminergic pathways have been implicated 
in the performance of tics based on the clinical ob-
servation that tics can be suppressed by dopamine 
antagonists and exacerbated by dopamine ago-
nists.71 Several studies using single photon emission 
computed tomography or positron emission tomog-
raphy revealed higher densities of presynaptic do-
pamine transporters and postsynaptic dopamine 
D2 receptors (D2Rs) in the basal ganglia of TS pa-
tients.44,72,73 A hypothesis of decreased tonic (basal) 
and increased phasic (spike-dependent) release of 
presynaptic dopamine in the striatum of TS patients 
might explain the compensatory increase in postsyn-
aptic D2R densities, resulting in higher dopaminergic 
activity and subsequent tic symptoms.74 Postmortem 
brain immunohistochemistry analysis of TS subjects 
also demonstrated elevated amounts of dopamine 
transporters and D2Rs in the frontal cortex.75−77 This 
evidence provides strong support to the idea that 
increased dopaminergic innervations in the brain 
play a critical role in the pathophysiology of TS.
6.  Assessment and Diagnosis
Clinical evaluation of child or adolescent with TS 
should properly consider the “whole person,” and 
not just focus on the abnormal motor symptoms. 
A complete assessment should include detailed 
perinatal, developmental, familial, medical and 
psychosocial histories, along with screening for 
ADHD, OCD and learning difficulties.
The clinician’s responsibility is to clarify the 
degree of impairment that tics and/or other co-
morbidities cause in the child’s emotional, social, 
familial and school experiences. The diagnosis of 
TS is currently based on the criteria proposed by the 
Diagnostic and Statistical Manual of Mental Disorders, 
4th edition, Text Revision (DSM-IV-TR; Table 1).78 
The proposed revisions of these criteria for DSM-V 
are now available online (www.dsm5.org). Somewhat 
different criteria are offered by the International 
Classification of Disease and Related Health Problems, 
10th Revision (ICD-10).79
Once a diagnosis of TS has been established, 
continuous monitoring of tic symptoms over a pe-
riod of time is necessary to assess their severity, 
fluctuations, and impact on the patient’s life. Long 
term follow-up is aided by the use of a standard 
rating instrument for tic severity evaluation, such 
as the Yale Global Tic Severity Scale.80 Tics can 
mimic the symptoms of other involuntary move-
ment disorders and are sometimes misdiagnosed 
as dystonia, chorea, myoclonus, tardive dyskinesia 
or other hyperkinetic movement disorders.81 Being 
suppressible and often preceded by sensory urges 
are the key features differentiating tics from other 
movement disorders.81 A thorough neurological ex-
amination is important to rule out other abnormal-
ities but is often normal apart from the tics. Some 
Glutamatergic projections
GABAergic projections
GABAergic projections from FSN
Acetylcholinergic projections from TAN
Dopaminergic projections from SNc
Prefrontal cortex Motor cortex Sensorimotor cortex
Mesiofrontal cortex
Limbic cortex
SS TAN
Striatum
Ventromedial
Dorsal lateral
SNc
FSN
MS
SS
Hippocampus
FSN
MS
MS
GPe
STN
Cerebellum
SNr
Nonspecific n.
Specific n.
Thalamus
GPi
Figure 2 Schematic diagram of the major connections of the basal ganglia associated with Tourette syndrome (adapted 
from Leckman, 200666). MS = matrisomal medium spiny neurons; SS = striosomial medium spiny neurons; TAN = tonically 
active neurons; FSN = fast-spiking interneurons; GPe = globus pallidus, pars externa; GPi = globus pallidus, pars interna; 
SNr = substantia nigra, pars reticulata; SNc = substantia nigra, pars compacta; STN = subthalamic nucleus.
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severely affected TS patients may have “soft signs” 
on neuromaturational examination, suggesting dis-
turbances in motor control, which may have prog-
nostic significance.82 Electroencephalo graphy and 
neuroimaging studies are not indicated unless co-
existing seizures or changes in mental status are 
suspected. No laboratory test for positive diagno-
sis of TS is currently available.29
7.  Treatment
The treatment goal for TS children should focus on 
maximizing their potential in school settings and so-
cial functioning, rather than attempting to eliminate 
their tics. Education for TS children and their fam-
ilies about the natural course of TS and the potential 
impact of stress on tics is warranted to promote bet-
ter tolerance, and may have a positive influence on 
the course of the illness. Participation in physical ex-
ercise activities, learning special talents (e.g., play-
ing musical instruments), and maintaining good sleep 
hygiene are often encouraged.29 No specific diet has 
proven beneficial for relieving tics, but it is advisable 
to avoid caffeine, which may exacerbate tics in some 
children.83 The decision to start treating tics should 
depend on their severity, and the interference in 
daily life caused by the tic symptoms themselves.84 
When patients present with other comorbidities, 
such as ADHD or OCD, it is usually preferable to treat 
these comorbid disorders first, since their successful 
treatment often diminishes tic severity.
7.1.  Anti-tic medications
Two classes of drugs are widely used to control tics 
in TS: α2-adrenergic agonists and neuroleptics 
(Table 285). The efficacy of α2-adrenergic agonists, 
including clonidine and guanfacine, is supported 
by results of randomized, placebo-controlled clinical 
trials.86,87 Clonidine reduces central noradrenergic 
activity by stimulation of presynaptic α2-adrenergic 
autoreceptors, while guanfacine acts on postsynap-
tic α2-adrenergic receptors. Clonidine is usually the 
first choice in previously untreated TS patients. 
A large randomized controlled trial also demon-
strated that clonidine was effective in reducing 
ADHD and tic severity in TS children with comorbid 
ADHD.88 The main side effects of clonidine are se-
dation and hypotension. Dose reduction is required 
for these side effects, and periodic blood pressure 
monitoring is advised because of possible rebound 
hypertension associated with abrupt discontinua-
tion. Guanfacine acts longer than clonidine, and 
hypotension is less commonly encountered.
Neuroleptics (or antipsychotics) are the most 
effective drugs for treating tics; they act primarily 
by blocking dopamine receptors and thereby decreas-
ing dopaminergic input to basal ganglia. Typical 
neuroleptics such as haloperidol and pimozide have 
been used successfully in the treatment of TS since 
the 1960s. However, all these typical neuroleptics are 
associated with significant side effects, e.g., ex-
trapyramidal syndrome and drug-induced parkin-
sonism. Thus atypical neuroleptics, which act by 
partially blocking both dopamine and serotonin re-
ceptors, are usually better choices than typical neu-
roleptics because they show reduced incidence of 
side effects. Risperidone has been demonstrated 
to be superior to placebo and clonidine in several 
double-blind trials in children with TS.89,90 The most 
common adverse effects of risperidone were weight 
gain, sedation, sleep disturbance and abnormal lipid 
metabolism. Ziprasidone was also shown to be bet-
ter than placebo in a small, double-blind study in TS 
children.90,91 Ziprasidone has a lower risk of weight 
gain, but concern about its potential to alter car-
diac conduction, especially QTc prolongation, still 
remains. Aripiprazole is a novel neuroleptic that has 
been demonstrated to be effective in treating TS 
children in several open-label studies,92,93 but ran-
domized controlled, double-blind trials have not 
been reported.
7.2.  Habit reversal therapy
Habit reversal therapy (HRT) is the first behavior 
therapy that has shown promising results in reducing 
tic severity in TS children.94 The major components 
of HRT consist of awareness training and compet-
ing response practice. Awareness training is designed 
to increase patients’ ability to detect the situation 
in which tics occur and the earliest signs of tic onset. 
Once patients are able to identify the premonitory 
urges, they are taught to use a competing response 
Table 1  Diagnostic criteria for Tourette syndrome 
(Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition, Text Revision)78
1.  Both multiple motor and one or more vocal tics 
have been present at some time during the 
illness, although not necessarily concurrently
2.  The tics occur many times (usually in bouts) 
nearly every day or intermittently throughout a 
period of more than a year; during this period 
there was never a tic-free period of more than 
3 consecutive months
3.  Onset before the age of 18 years
4.  The disturbance is not due to the direct 
physiological effects of a substance (e.g., 
stimulants) or a general medical condition (e.g., 
Huntington’s chorea or postviral encephalitis)
Tourette syndrome in children 261
in a movement or vocalization that is incompatible 
with the movements or sound production required 
to perform the tic. Indeed, HRT seems to be a prom-
ising option for treating TS patients with prominent 
premonitory urges.
7.3.  Other developing therapies
Repetitive transcranial magnetic stimulation (rTMS) 
involves the repetitive generation of a brief, pow-
erful magnetic field by a small coil positioned over 
the skull, inducing an electric current in the brain. 
This noninvasive brain stimulation may change the 
abnormal cortical excitability in TS patients.95 A 
recent study using low-frequency rTMS over the bi-
lateral supplementary motor area significantly im-
proved tic severity in five TS patients.96 However, 
this study was unblinded and uncontrolled; further 
randomized, sham-controlled trials of rTMS are 
needed to confirm its efficacy.
Deep brain stimulation (DBS) is a stereotactic, 
neurosurgical technique that places electrodes in 
certain brain regions (e.g., globus pallidus, thala-
mus) to suppress abnormal oscillatory activity. DBS 
has been used successfully to treat Parkinson’s dis-
ease, dystonia and other movement disorders. 
Several case series using DBS for treatment of pa-
tients with refractory TS have reported significant 
improvement of tic severity after the proce-
dure.97,98 Infection, stroke, nausea and blurred vi-
sion are uncommon side effects. As an invasive 
therapy, DBS is currently only advisable for se-
verely affected, treatment-refractory TS adults.
8.  Future Perspectives
Developing proper animal models of TS, though 
difficult, will be important for studying the patho-
physiology and pharmacologic treatment of tic 
symptoms. If current candidate genes such as 
SLITRK1 and HDC are confirmed to have major ef-
fects, then valid animal models of TS should be 
forthcoming. Based on the evidence of relatively 
reduced amounts of cholinergic TANs and GABAergic 
parvalbumin-positive FSNs in the striatum of TS 
patients, it is possible to develop animal models of 
TS by specifically destroying these neurons or in-
terneurons with immunotoxic antineuronal anti-
bodies or genetically engineered viral vectors. On 
the other hand, at least one randomized sham-
controlled study using rTMS for the treatment of 
TS is being conducted at present. If this study con-
firms its efficacy, rTMS will become a promising 
treatment for TS.
TS is considered to be a model disorder for 
studying the interactions among genetic vulnera-
bilities, environmental effects, and neurobiologi-
cal systems active during early brain development. 
The results of research on TS will enhance our un-
derstanding not only of TS itself, but also that of 
many other neurological and behavioral disorders.
Table 2  Medications for Tourette syndrome (adapted from Bloch, 200885)
 CEBM evidence  
Starting dose
 
Typical dose 
Side effects grade*    
 Adults Children 
(mg/d)
 
(mg/d)
α2-agonists
 Clonidine Low High 0.025−0.05 0.1−0.3 Sedation, hypotension 
 Guanfacine Low High 0.5 1.5−3 Sedation, lightheadedness
Typical neuroleptics
 Haloperidol High High 0.25−0.5 1−4 EPS, sedation, weight gain
 Pimozide High High 0.5−1 2−8 QTc prolongation, sedation
 Fluphenazine Low Low 0.5−1 1.5−10 Better tolerated than haloperidol
Atypical neuroleptics
 Risperidone High High 0.25−0.5 1−3 Sedation, weight gain, abnormal 
      lipid metabolism
 Ziprasidone Low High 20 20−80  QTc prolongation, sedation, 
 weight gain
 Aripiprazole Low Low 2.5−5 10−20 Sedation, weight gain
 Olanzapine Low Low 2.5−5 10−20 Sedation, weight gain
 Quetiapine Low Low 25−50 75−250 Sedation, weight gain
*High CEBM evidence grade indicates efficacy in randomized, double-blind trials, where as low grade indicates probable efficacy 
in an observational study. CEBM = Center for Evidence-based Medicine; EPS = extrapyramidal syndrome.
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